In terms of consumer and patient behavior changes, we collected information from a sample of key Italian hospitals about developments on three different aspects.
Since February, new COVID-19 cost centers have been created. The IQVIA samples counts 369 new COVID-19 wards, differentiated by treatments (general, pneumology, intensive ward, first aid/triage and infectiology).
Collecting data from different hospitals, we are now able to provide a clearer representation on the evolution of prescription medicine consumption in relation to COVID-19. Based on raw data, we have seen a rise of drugs related to COVID-19 potential treatments (Plaquenil, antivirals, Roactemra and other antirheumatics, heparins), intensive care (anesthetics, muscle relaxants, analgesics, narcotics, physiological solutions, etc.) and then treatments for viral symptoms (paracetamol/Ibuprofen, corticosteroids, antibacterial antibiotics/antimicrobial).
In terms of medical devices, there has been an increase in personal safety devices (mask, glasses, gowns, gloves), intensive and sub-intensive care (endotracheal tubes, breathing machines) and disinfectants (gel).